Loading…
← CockpitCompetitor Analysis › CBAV.MC Clinica Baviera SAOpen in the cockpit ↗

Clinica Baviera SACBAV.MCCompetitor analysis, valuation and peers

Spain · EUR·Health Care›Hospital/Nursing Management

Spanish-German chain of ophthalmology clinics specializing in laser vision correction, cataract and eye surgery.

≈ A smaller, European vision-correction/cataract clinic chainMomentum strong 60
Mkt cap
$1.01B
US dollars, full cap
Free float
18%
of shares outstanding
$/day
$124,110
20-day average traded
Fwd P/E
20.1×
forward earnings
ROIC−WACC
+59.6 pp
WACC 8.4%
Hurdle
-17 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · EUR€56.40
1D+1.1%
1W+7.2%
1M+3.7%
3M-4.1%
6M+2.2%
YTD+13.5%
1Y+33.6%
ATR %2.5%
52w lowhigh9.0% off high

What Clinica Baviera does

Spanish-German chain of ophthalmology clinics specializing in laser vision correction, cataract and eye surgery.

Laser vision correction is mostly paid for out of pocket by patients, which makes that line behave like consumer spending; cataract and other eye surgery are paid in part by insurers or public systems. Results depend on patient volumes and on how many clinics operate.

In one line: A smaller, European vision-correction/cataract clinic chain.

Products and services

  • Laser vision correction (LASIK)
  • Cataract surgery
  • Intraocular lens implants
  • Ophthalmology consultations

Customers

  • Patients seeking vision correction/cataract care

Where it sits in the supply chain

  • Health Care
  • Healthcare services
  • Ophthalmology clinic chain

What could go right

  • Aging population driving cataract demand
  • Clinic footprint expansion

What could go wrong

  • Elective-procedure demand sensitivity to income
  • Competition from private-equity-backed chains

Moat: narrow (brand, scale, installed base). Largest branded eye-clinic network in Iberia/Germany gives referral and marketing scale advantages.

Headquarters: Madrid, Spain · Founded: 1992 · Employees: 1,910

Named competitors

  • Innova Ocular (private) private or unlisted
  • Optical Express (private) private or unlisted
  • Sanoptis (private) private or unlisted
  • Independent ophthalmology practices private or unlisted

Clinica Baviera at a glance

Size Clinica Baviera (CBAV.MC) is a Spain Health Care company (Hospital/Nursing Management) with a market value of $1.01B, the 68th largest of 93 Spain companies the cockpit tracks. Shares closed at €56.40 on 18 Nov 2026.

Performance Over six months the shares gained 2.2%, against -3.8% for the median peer and +5.3% for the Spain market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 10.9% over the last twelve months (peer median +14.8%); the operating margin is 20.4% (peer median 10.3%).

Valuation It trades at 20.1× forward earnings against a peer median of 40.4× (3rd cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -17 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 59.6 points above its cost of capital (8.4% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026CBAV.MC 101Peer median 94
Six months, rebased to 100: Clinica Baviera against the median of its 20 peers (local-currency closes).

Clinica Baviera financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€317M€302M€263M€225M€198M
Revenue growth—+15%+17%+13%—
Gross profit€64.5M€127M€112M€95.0M€86.9M
EBITDA€90.5M€106M€92.8M€67.0M€57.1M
Net income€46.8M€42.1M€40.2M€36.0M€29.5M
Free cash flow€46.9M€47.7M€36.1M€35.2M€39.0M
Capital expenditure€30.8M€30.0M€26.5M€22.7M€14.0M
Total debt€9.90M€69.2M€61.3M€47.3M€47.8M

Quarterly statements and history in the cockpit →

Clinica Baviera competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-10%0%+10%+20%JLHLGDSRHKHCGPARKHOSPSA50YATHARTHCVSGBSLSPIKOVAI301293RAINBOWAEVSARTEMISMED301267EXECBAV.MC6-month return →1-month return →
Up and to the right = strong over both horizons. Clinica Baviera is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%50×100×JLHLRHKHCGPARKHOSPSYATHARTHCVSGBSL301293RAINBOWAEVSSIAARTEMISMEDEXECBAV.MCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Clinica Baviera is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%GDSPARKHOSPSA50CVSGBSLSPIKOVAIRAINBOWAEVS000516ARTEMISMED301267CBAV.MCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Clinica Baviera is the large dot.

Clinica Baviera competitors and peer comparison

How Clinica Baviera compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Clinica Baviera against its 20 peers (data as of 18 Nov 2026)
MeasureCBAV.MCPeer medianRank in peer set
1-month return+3.7%+1.6%9th highest of 20
6-month return+2.2%-3.8%9th highest of 20
Distance from 52-week high-9.0%-18.4%6th highest of 21
Revenue growth (TTM)+10.9%+14.8%9th lowest of 21
Operating margin20.4%10.3%4th highest of 21
Forward P/E20.1×40.4×3rd cheapest of 16
Growth the price implies (Req g, 7 yrs)2.3%15.8%3rd least demanding of 15
Growth delivered (Del g)+19.7%+10.3%4th highest of 15
Hurdle (Req g minus delivered)-17.4 pp+4.8 ppleast demanding of 15
ROIC minus cost of capital+59.6 pp-2.7 pphighest of 21
EV / EBITDA9.7×21.7×4th cheapest of 16
Net debt / EBITDA-0.5×2.1×2nd least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Clinica Baviera CBAV.MCSpain$1.01B+2%+11%20%20.1×2.3%+19.7%
Jupiter Life Line Hospitals JLHL.NSIndia$1.01B+9%+17%16%48.8×n/an/a
Ramsay Generale de Sante GDS.PAFrance$969M-25%+3%4%n/a6.1%+6.0%
Rhon-klinikum RHK.DEGermany$1.06B+15%+4%-51%22.5×n/an/a
Paras Healthcare PARASHLTH.NSIndia$962Mn/a+24%11%n/an/an/a
HealthCare Global Enterprises HCG.NSIndia$955M-7%+13%8%88.8×n/an/a
Park Medi World PARKHOSPS.NSIndia$1.10B-4%+21%21%30.6×22.1%+10.2%
Thomson Medical A50.SISingapore$923M-18%+6%10%n/a21.2%+11.8%
Yatharth Hospital and Trauma Care Services YATHARTH.NSIndia$1.13B+31%+50%16%49.4×n/an/a
CVS CVSG.LUnited Kingdom$1.22B+17%+6%11%14.6×14.2%+6.9%
Raffles Medical BSL.SISingapore$1.23B-13%-3%11%27.1×-2.7%+6.1%
Spire Healthcare SPI.LUnited Kingdom$1.31B+11%+2%8%25.1×10.0%+11.4%
Kovai Medical Center & Hospital KOVAI.NSIndia$759M+22%+17%21%n/a17.4%+18.1%
Sanbo Hospital Management 301293.SZChina$1.35B-29%+17%6%135.5×n/an/a
Rainbow Childrens Medicare RAINBOW.NSIndia$1.37B-7%+23%22%40.4×30.7%+21.2%
Aevis Victoria AEVS.SWSwitzerland$1.43B+8%+15%-6%106.8×26.5%+10.2%
Xi'an International Medical Investment 000516.SZChina$1.46B-2%-1%-2%n/a12.7%+20.6%
Sienna Senior Living SIA.TOCanada$1.58B-8%+15%10%40.9×18.9%+8.6%
Artemis Medicare Services ARTEMISMED.NSIndia$582M+25%+15%13%42.3×48.5%+21.5%
Huaxia Eye Hospital 301267.SZChina$1.78B-18%+2%15%23.5×2.1%+10.4%
Extendicare EXE.TOCanada$1.91B-16%+36%9%19.3×10.8%+8.5%

Questions

Who are Clinica Baviera's main competitors?
Named competitors: Innova Ocular (private) (private or unlisted), Optical Express (private) (private or unlisted), Sanoptis (private) (private or unlisted), Independent ophthalmology practices (private or unlisted). The cockpit's measured peer set (industry) also includes Jupiter Life Line Hospitals (JLHL.NS), Ramsay Generale de Sante (GDS.PA), Rhon-klinikum (RHK.DE), Paras Healthcare (PARASHLTH.NS), HealthCare Global Enterprises (HCG.NS), Park Medi World (PARKHOSPS.NS).
Is Clinica Baviera expensive compared with its peers?
On forward p/e it trades at 20.1× against a peer median of 40.4×, 3rd cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -17 pp: the price already allows for a slowdown.
How has Clinica Baviera stock performed?
Over six months to 18 Nov 2026 the shares returned +2.2% against -3.8% for the median peer; over one year +33.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.